Treatment Options
Not every modality works for every person on dialysis. DPC believes people affected by kidney failure should be able to choose the modality that works best for them. There are a variety of factors that people on dialysis might weigh in order to choose one modality over another. These include employment status, insurance coverage, the availability of services available and personal preference. DPC strives to ensure all modalities are free of financial and regulatory barriers so people affected by kidney failure can live the active and fulfilling lives they want to live.
Related Information
Giving Thanks
As we approach Thanksgiving this week, DPC would like to take a moment to thank all of our phenomenal Board Members, Patient Ambassadors, and kidney advocates for sharing their stories and fighting to improve the [...]
DPC Comment Letter to CMS Recounts Heartbreaking Story of Rural Dialysis Clinic Closure
DPC has submitted its comments responding to this year’s Medicare ESRD Payment Rule. The Medicare agency is proposing a payment update of only 1.9%, which doesn’t keep pace with increasing costs. According to the [...]
DPC’s Letter to Dr. Mehmet Oz, Administrator at Centers for Medicare & Medicaid Services, on ESRD Prospective Payment System
August 27, 2025 The Honorable Mehmet Oz Administrator Centers for Medicare & Medicaid Services 200 Independence Avenue, SW Washington, DC 20001 Re: CMS-1830-P - End-Stage Renal Disease Prospective Payment System Dear Dr. Oz: Dialysis [...]
DPC Asks Medicare Officials to Reverse Pruritis Drug Fiasco
In a letter to the Center for Medicare and Medicaid Services (CMS), Dialysis Patient Citizens (DPC) asked for a “do-over” in the rollout of Korsuva, a drug that treats ESRD-related pruritis. Medicare makes an add-on [...]
DPC’s Letter to Hon. Jonathan Blum, Principal Deputy Administrator for CMS, on New Drugs in the ESRD PPS
June 11, 2024 The Honorable Jonathan Blum Principal Deputy Administrator Centers for Medicare & Medicaid Services 200 Independence Avenue, SW Washington, DC 20515 Re: New drugs in the ESRD PPS Dear Principal Deputy Administrator [...]
DPC Seeks Information on Patients’ Experience With Itching
A couple of years ago, a new drug was approved to treat ESRD-related pruritis. Medicare approved an additional payment for the drug Korsuva for a period of 2 years. But, because of the short expiration [...]
